Advances in HIV therapeutics. A report from the 2017 Conference on Retroviruses and Opportunistic Infections (CROI): Seattle, Washington, USA - February 13-16, 2017

S. A. Rizza; W. El Atrouni; R. Bhatia; Z. Temesgen

doi:10.1358/dof.2017.042.04.2625317

Advances in HIV therapeutics. A report from the 2017 Conference on Retroviruses and Opportunistic Infections (CROI): Seattle, Washington, USA - February 13-16, 2017

S. A. Rizza, W. El Atrouni, R. Bhatia, Z. Temesgen

Infectious Diseases

Research output: Contribution to journal › Article › peer-review

Abstract

The 2017 Conference on Retroviruses and Opportunistic Infections (CROI) convened scientists, clinicians, and policy makers from around the world to share and discuss important developments in HIV infection and related diseases. Highlights of this year's CROI include advances in HIV prevention, clinical trials of established and novel antiretroviral agents, and strategies for HIV cure.

Original language	English (US)
Pages (from-to)	241-249
Number of pages	9
Journal	Drugs of the Future
Volume	42
Issue number	4
DOIs	https://doi.org/10.1358/dof.2017.042.04.2625317
State	Published - Apr 2017

Keywords

Bictegravir
Cabotegravir
Dapivirine
Doravirine
Elsulfavirine
GS-986
Ibalizumab
MK-8591
PRO-140
Romidepsin
UB-421
Vesatolimod

ASJC Scopus subject areas

Pharmacology
Pharmacology (medical)

Access to Document

10.1358/dof.2017.042.04.2625317

Cite this

@article{12619f661c334e078e31a2da510782dd,

title = "Advances in HIV therapeutics. A report from the 2017 Conference on Retroviruses and Opportunistic Infections (CROI): Seattle, Washington, USA - February 13-16, 2017",

abstract = "The 2017 Conference on Retroviruses and Opportunistic Infections (CROI) convened scientists, clinicians, and policy makers from around the world to share and discuss important developments in HIV infection and related diseases. Highlights of this year's CROI include advances in HIV prevention, clinical trials of established and novel antiretroviral agents, and strategies for HIV cure.",

keywords = "Bictegravir, Cabotegravir, Dapivirine, Doravirine, Elsulfavirine, GS-986, Ibalizumab, MK-8591, PRO-140, Romidepsin, UB-421, Vesatolimod",

author = "Rizza, {S. A.} and {El Atrouni}, W. and R. Bhatia and Z. Temesgen",

year = "2017",

month = apr,

doi = "10.1358/dof.2017.042.04.2625317",

language = "English (US)",

volume = "42",

pages = "241--249",

journal = "Drugs of the Future",

issn = "0377-8282",

publisher = "Prous Science",

number = "4",

}

TY - JOUR

T1 - Advances in HIV therapeutics. A report from the 2017 Conference on Retroviruses and Opportunistic Infections (CROI)

T2 - Seattle, Washington, USA - February 13-16, 2017

AU - Rizza, S. A.

AU - El Atrouni, W.

AU - Bhatia, R.

AU - Temesgen, Z.

PY - 2017/4

Y1 - 2017/4

N2 - The 2017 Conference on Retroviruses and Opportunistic Infections (CROI) convened scientists, clinicians, and policy makers from around the world to share and discuss important developments in HIV infection and related diseases. Highlights of this year's CROI include advances in HIV prevention, clinical trials of established and novel antiretroviral agents, and strategies for HIV cure.

AB - The 2017 Conference on Retroviruses and Opportunistic Infections (CROI) convened scientists, clinicians, and policy makers from around the world to share and discuss important developments in HIV infection and related diseases. Highlights of this year's CROI include advances in HIV prevention, clinical trials of established and novel antiretroviral agents, and strategies for HIV cure.

KW - Bictegravir

KW - Cabotegravir

KW - Dapivirine

KW - Doravirine

KW - Elsulfavirine

KW - GS-986

KW - Ibalizumab

KW - MK-8591

KW - PRO-140

KW - Romidepsin

KW - UB-421

KW - Vesatolimod

UR - http://www.scopus.com/inward/record.url?scp=85019225489&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019225489&partnerID=8YFLogxK

U2 - 10.1358/dof.2017.042.04.2625317

DO - 10.1358/dof.2017.042.04.2625317

M3 - Article

AN - SCOPUS:85019225489

SN - 0377-8282

VL - 42

SP - 241

EP - 249

JO - Drugs of the Future

JF - Drugs of the Future

IS - 4

ER -

Advances in HIV therapeutics. A report from the 2017 Conference on Retroviruses and Opportunistic Infections (CROI): Seattle, Washington, USA - February 13-16, 2017

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this